https://doi.org/10.33472/AFJBS.6.6.2024.7739-7754

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

The Therapeutic Potential of Felbamate: An In-Depth Review of Mechanisms, Efficacy, Safety, and Future Directions

Poonam Maurya[1, 2], Rishikesh Gupta[1*], Peeyush Bhardwaj[1], Alok Mahor[1]

[1]Institute of Pharmacy, Bundelkhand University, Jhansi, Uttar Pradesh, India, 284128
[2]Shambhunath Institute of Pharmacy, AKTU, Prayagraj, Uttar Pradesh, India, 211015
***Corresponding Author**: Email: rishikeshgupt@gmail.com

Article Info

Volume 6, Issue 6, July 2024

Received: 03 June 2024

Accepted: 04 July 2024

Published: 30 July 2024

doi: 10.33472/AFJBS.6.6.2024.7739-7754

ABSTRACT:

Felbamate acknowledged as an antiepileptic medicine since the 1990s, has garnered scientific interest due to its unique pharmacological properties and potential therapeutic uses beyond epilepsy. This comprehensive scientific review aims to thoroughly examine felbamate's chemistry, focusing on its mechanisms of action, which include the modulation of NMDA and GABA receptors. These actions contribute to its antiepileptic efficacy and its potential in synaptic plasticity and neuroprotection, thus providing versatility for potential neurological uses. The review also assesses felbamate's therapeutic efficacy, especially in treatment-resistant epilepsy, where standard medications often fail. Additionally, the safety profile is evaluated, highlighting risks such as aplastic anemia and hepatic dysfunction, essential for risk-benefit analysis. Significantly, considerable scientific interest in felbamate extends beyond its use in treating epilepsy. Ongoing research efforts are shedding light on its potential neuroprotective properties, particularly in the context of neurodegenerative disorders like Alzheimer's and Parkinson's disease. This interest is driven by felbamate's ability to regulate synaptic plasticity and reduce neuroinflammatory processes. This study provides a comprehensive overview of the current scientific understanding of felbamate, encompassing its various mechanisms, clinical effectiveness, safety issues, and potential avenues for future research. The unique pharmacological profile of felbamate, along with its increasing application in the field of neurology, solidifies its status as a topic of ongoing scientific inquiry and highlights its potential importance in neurological treatments.

Keywords: Felbamate; epilepsy; synaptic plasticity; neuroprotection; neurodegenerative disorders.

© 2024 Poonam Maurya, This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and

1. Introduction

Epilepsy is a multifaceted neurological condition considered by the repetitive occurrence of seizures that has a global impact, affecting a population of over 50 million individuals (WHO, 2023). Felbamate was synthesized in the year 1950 while investigating compounds with anxiolytic properties (Dieckhaus et al., 2002). The antiepileptic effects of the substance were identified three decades later and were granted approval by the Food and Drug Administration (FDA) in 1993 for treating partial seizures, with or without secondary generalization, in adults and for managing Lennox-Gastaut syndrome. Felbamate was the initial antiepileptic drug (AED) to be introduced after the authorization of valproic acid in 1978 (Vidaurre et al., 2017). Felbamate (FBM) is a compound derived from meprobamate that possesses both anticonvulsant and neuroprotective characteristics. This substance has the ability to impede the function of voltage-dependent sodium channels and has the potential to enhance the flow of gamma-aminobutyric acid (GABA) currents (Borowicz et al., 2004; Palmer & McTavish, 1993). Due to its distinct pharmacological properties and evolving therapeutic potential, felbamate has attracted considerable scientific and clinical interest. However, in August 1994, the recommendation to restrict its usage was made in response to cases of aplastic anemia (Hanrahan & Carson, 2023). The pharmaceutical product received a 'Black Box' warning due to its association with aplastic anemia and hepatic failure (Brown & Aiken, 1998; Thakkar et al., 2015). The United States granted permission for the first generic formulation of felbamate in 2011. Given the possibility of additional pharmaceutical companies entering the market with generic versions of felbamate, it becomes imperative to assess the efficacy and practicality of this particular prescription.

The discovery of Felbamate provided a distinctive strategy for the management of seizures. Its mechanisms of action, characterized by interactions with gamma-aminobutyric acid (GABA) receptors and N-methyl-D-aspartate (NMDA) receptors, not only underpin its antiepileptic efficacy but also extend its relevance to synaptic plasticity and neuroprotection, raising the possibility of wider applications in the realm of neurological disorders (Sills & Rogawski, 2020). When traditional antiepileptic medications fail to control seizures in patients with treatment-resistant epilepsy, Felbamate steps in as a crucial player. Additionally, new research initiatives are revealing Felbamate's potential neuroprotective properties in neurodegenerative disorders including Parkinson's and Alzheimer’s disease, broadening the scope of the drug's applicability beyond epilepsy. This comprehensive study aims to analyze the various aspects of Felbamate, including its mechanisms of action, clinical efficacy, safety issues, and potential areas for further scientific investigation. The significance of Felbamate's unique pharmacological profile and increasing relevance in neurology highlights the importance of further investigating its therapeutic potential in neurological treatments.

1. Chemistry of Felbamate

Felbamate, also known as 2-phenyl-1,3-propanediol dicarbamate, is chemically similar to meprobamate, a popular anxiolytic of the 1960s (Graves, 1993; Wagner, 1994). It is structurally and pharmacologically unique, however. Lipophilic felbamate appears as a white powder that is only slightly soluble in ethanol and substantially soluble in organic solvents like dimethyl sulfoxide (Figure 1).




Figure 1 Chemical Structure of Felbamate

2. Mechanisms Of Action Of Felbamate

Felbamate possesses a distinctive pharmacological makeup that sets it apart from conventional antiepileptic drugs, hence distinguishing its therapeutic profile (Figure 2) (Löscher et al., 2021a). Its mechanisms of action rely on a complex pharmacological profile that defies easy categorization, making it both a scientific and clinically interesting topic. The precise mechanism by which felbamate exerts its effects remains uncertain; however, it is believed to involve the blockade of voltage-gated sodium channels, interference with both N-methyl-D-aspartate (NMDA) and non-NMDA subtypes of glutamate receptors, and allosteric modulation of gamma-aminobutyric acid (GABA) receptors (Ilo E Leppik & White, 2015). This intervention decreases heightened neuronal activity by decreasing the function of voltage-gated sodium channels, and interferes with the release of neurotransmitters by blocking calcium currents. Although felbamate has a limited influence on GABA function, it does not exhibit any sedative properties or negative impact on cognitive performance (Brodie, 2010; Corradetti & Pugliese, 1998; Czapinski et al., 2005; Pellock et al., 2006).




Figure 2: Mechanism of Action of Felbamate

3.1 MODULATION OF N-METHYL-D-ASPARTATE (NMDA) RECEPTORS

The antiepileptic effects of felbamate are achieved through the modulation of N-methyl-D-aspartate (NMDA) receptors. These receptors are ion channels that have a significant impact on synaptic plasticity, as well as processes related to learning and memory. These receptors play a crucial role in the propagation of seizure activity and modulating neuronal excitability. The binding of Felbamate to the NR2B subunit of NMDA receptors results in a decrease in heightened neuronal excitation by inhibiting the influx of calcium ions through the channels of the receptor. This phenomenon has a role in the reduction of epileptiform activity and the inhibition of the spread of seizures.

3.2 ENHANCEMENT OF GAMMA-AMINOBUTYRIC ACID (GABA) TRANSMISSION

Gamma-aminobutyric acid (GABA)ergic neurotransmission, a crucial inhibitory mechanism in the brain, is likewise enhanced by felbamate. Inhibition and excitation of neurons are balanced by GABAergic transmission. The effects of felbamate include lengthening the opening of GABA-gated chloride channels and improving GABA's affinity for its receptors (Löscher et al., 2021b). By reducing neuronal excitability and increasing inhibitory transmission, decreases the likelihood of seizure initiation and propagation.

3.3 INHIBITION OF VOLTAGE-GATED SODIUM CHANNELS

Action potential generation and propagation in neurons depend on voltage-gated sodium channels. By inhibiting these channels, felbamate reduces the input of sodium ions and, as a result, reduces the excitability of neurons. Felbamate may prevent the emergence of abnormal neuronal discharges that characterize seizures by altering sodium channel function.

3.4 GLUTAMATE REGULATION AND NEUROPROTECTION

Beyond its interactions with NMDA receptors, felbamate also modulates glutamatergic transmission. Felbamate can lessen the excitotoxicity connected with epileptic seizures by lowering the excessive release of glutamate, a significant excitatory neurotransmitter. This neuroprotective action may help to avoid neuronal damage brought on by seizures and promote overall neuronal health.

It is believed that felbamate's distinctive effectiveness profile results from the fusion of these different modes of action. By addressing both the excessive excitability of neurons and the propagation of epileptiform activity, felbamate may have a broader impact on several seizure types, including focal and generalized seizures. Additionally, patients who have grown resistant to AEDs that focus on a single target benefit from this multifaceted approach.

4. IMPACT ON SYNAPTIC PLASTICITY

The impact of Felbamate on synaptic plasticity is a crucial component of its many modes of action in relation to neurological diseases. Synaptic plasticity is a fundamental mechanism that governs the capacity of synapses to undergo strengthening or weakening processes over a period of time. This phenomenon serves as the foundation for various cognitive processes such as learning, memory formation, and the adaptive response of neural networks to external stimuli. The modulatory actions of Felbamate on neuronal plasticity offer valuable insights into its potential as a therapeutic agent.

4.1 LONG-TERM DEPRESSION (LTD) AND LONG-TERM POTENTIATION (LTP)

The modulation of synaptic plasticity, a crucial aspect of neuronal function, has been demonstrated in the case of felbamate, which affects both Long-Term Potentiation (LTP) and Long-Term Depression (LTD). Long-term potentiation (LTP) is a process that entails the maintenance of synaptic connections, so permitting improved communication between neurons. Conversely, long-term depression (LTD) refers to the weakening of synaptic connections, which promotes the elimination of unnecessary synapses and the refinement of neural circuits. The capacity of Felbamate to impact these physiological processes implies its potential involvement in regulating the dynamics and adaptability of neural networks.

4.2 NMDA RECEPTOR-MEDIATED SYNAPTIC PLASTICITY

The impact of Felbamate on synaptic plasticity is mostly influenced by its interactions with NMDA receptors. The activation of NMDA receptors plays a pivotal role in initiating synaptic plasticity. The modification of NMDA receptor activity by Felbamate has the potential to finely regulate the induction and maintenance of long-term potentiation (LTP) and long-term depression (LTD), thus impacting the strength and stability of synaptic connections. The modulation described has the potential to play a role in the drug's capacity to alleviate abnormal synaptic alterations linked to neurological disorders, specifically epileptiform activity.

4.3 GABA RECEPTOR-MEDIATED SYNAPTIC PLASTICITY

The enhancement of inhibitory GABAergic neurotransmission by felbamate represents an additional aspect of its influence on synaptic plasticity. Felbamate enhances inhibitory signaling, hence facilitating the preservation of an optimal balance between excitation and inhibition in neural networks. Maintaining this equilibrium is crucial for the accurate regulation of synaptic plasticity, hence preventing an overabundance of excitation that could potentially result in pathogenic modifications to synapses.

The comprehension of the impact of Felbamate on synaptic plasticity provides a comprehensive viewpoint of its potential therapeutic efficacy and emphasizes the significance of ongoing investigations into its mechanisms of action in diverse neurological illnesses.

5. PHARMACOKINETICS OF FELBAMATE

Felbamate, a derivative with a structural resemblance to the anxiolytic compound meprobamate, possesses unique pharmacokinetic properties. The recommended starting dose for children is usually three separate doses of 15 mg per kg of body weight each day. This may increase by 15 mg per kg every week. When treating adults, the recommended starting dosage is 400 mg three times a day, with further increases of 600 to 1,200 mg per day every week. While doses as high as 3,600 mg per day were utilized in pivotal studies that were submitted to the FDA, other trials have examined doses as high as 4,800 mg per day or more without experiencing any appreciable side effects (Laxer, 1994). It is suggested that patients already taking carbamazepine, phenytoin, or valproate reduce their dose of the concomitant medicine by about 25% before beginning felbamate treatment. The volume of distribution closely resembles the volume of total body water, which ranges from 0.76 to 0.85 liters per kg (Wagner, 1994). It demonstrates a relatively low binding affinity to plasma proteins (around 22-25%) and is primarily eliminated via renal excretion. Notably, the metabolism of felbamate may involve enzymes other than cytochrome P450 (CYP) (Benedetti 2000).

In clinical contexts, Felbamate (FBM) offers distinct advantages owing to its substantial bioavailability and prolonged duration of action. These attributes contribute to its ability to maintain consistent plasma concentrations in a proportional manner and its efficient absorption within the gastrointestinal system. In individuals not concurrently using other medications, the elimination half-life of FBM ranges from 16 to 22 hours. The elimination process involves both unchanged drug excretion as well as processes of hydroxylation and conjugation. Hepatic metabolism, primarily facilitated by liver enzymes, plays a significant role in the breakdown of FBM, with approximately 90% of the drug being excreted renally in urine. In vitro studies have demonstrated that FBM exhibits inhibitory effects on cytochrome P450 isoenzyme CYP2C19 at a concentration of 225 μmol/l. Following intravenous administration, FBM rapidly crosses the blood-brain barrier. Animal studies have indicated that levels of FBM peak between the second and sixth hour after oral administration. (Borowicz et al., 2004).

6. FELBAMATE-DRUG INTERACTION

Felbamate has been found to interact with various medications, including hormonal contraceptives, carbamazepine, phenytoin, valproic acid, clonazepam, lamotrigine, vigabatrin, oxcarbazepine, methsuximide, CYP2C19 enzymes, and CYP3A4 enzymes (Johannessen Landmark & Patsalos, 2010; Johannessen & Tomson, 2006; Rambeck et al., 1996). It has been observed to decrease the efficacy of hormonal contraceptives (Crawford, 2002; Patsalos, 2013; Reddy, 2010), reduce carbamazepine levels in the bloodstream, and increase its active metabolite. It has also been found to elevate oxcarbazepine levels and its dihydroxy metabolite, while having no substantial impact on the monohydroxy metabolite. It has also been observed to stimulate the metabolic process of felbamate, resulting in reduced steady-state concentrations. However, the concentrations of felbamate are not significantly affected by valproic acid, vigabatrin, and erythromycin (Benedetti, 2000; Loiseau, 1996; PERUCCA, 1996).

7. CLINICAL EFFICACY

7.1 EPILEPSY MANAGEMENT

Numerous clinical investigations and observations have yielded valuable information regarding the efficacy of this intervention in reducing seizure activity across various subtypes of epilepsy, encompassing both generalized and focal-onset seizures (I. E. Leppik et al., 1991; Perucca, 2000; Schmidt, 1993). Felbamate is mostly employed in specialist medical facilities to manage individuals diagnosed with Lennox Gastaut syndrome (Grosso et al., 2008; Pellock

et al., 2006), Doose syndrome, or refractory seizures (Hussain et al., 2020; Vidaurre et al., 2017).

7.1.1 Role in Treatment-Resistant Epilepsy

Establishing seizure control can prove to be a challenging objective for those diagnosed with treatment-resistant epilepsy. Felbamate has emerged as a promising therapeutic option in circumstances where other therapy routes have been tried, providing a potential reprieve for patients. The efficiency of this compound in reducing neuronal hyperexcitability, a prominent characteristic of treatment-resistant epilepsy, can be attributed to its mechanisms of action, which involve the regulation of N-methyl-D-aspartate (NMDA) receptors and gamma-aminobutyric acid (GABA) receptors. Within this particular context, the clinical efficacy of Felbamate serves to emphasize the necessity for different approaches to successfully deal with the many obstacles presented by refractory epilepsy (Cilio et al., 2001; Dozières-Puyravel et al., 2020; Hussain et al., 2020; Laxer, 1994).

7.2 NEW APPLICATIONS OUTSIDE OF EPILEPSY

Recent studies have provided valuable insights into the possible applications of felbamate beyond its established domain. In addition to its established efficacy in treating epilepsy, the mechanisms of action of Felbamate have garnered attention due to their potential relevance to several other neurological illnesses. These processes involve the modulation of synaptic plasticity and the enhancement of GABAergic neurotransmission. Ongoing investigations are currently examining the neuroprotective qualities of Felbamate in the context of neurodegenerative disorders, including Alzheimer's and Parkinson's disease. The motivation behind these investigations stems from the ability of Felbamate to attenuate neuroinflammatory cascades and synaptic dysfunction, indicating that it might be useful in the advancement of neurodegenerative processes (Calabresi et al., 2003).

8. SAFETY PROFILE

8.1 ADVERSE EFFECTS

Felbamate's safety profile can only be understood by taking a close look at all of the risks associated with it, but two in particular—aplastic anemia and hepatic dysfunction—have received a lot of attention from clinicians and researchers (Asconapé, 2002; Beghi, 2004).

8.1.1 Aplastic Anemia

The link between felbamate and aplastic anemia is a significant concern in clinical practice. Aplastic anemia is an infrequent but significant hematological condition characterized by diminished hematopoiesis in the bone marrow, resulting in decreased production of erythrocytes, leukocytes, and thrombocytes. Currently, there have been a total of 34 documented instances of aplastic anemia (Kaufman et al., 1997; Wallace, 1996), with a majority of cases originating from the United States. Out of the aforementioned cases, thirteen individuals experienced fatal outcomes, while eleven people successfully attained full recovery. The epidemiological review of felbamate-associated aplastic anemia was undertaken by Kaufman et al. The study utilized a United States exposure rate of 110,000 individuals. The estimated incidence was probably 127 per million, with a range of 27 to 209 per million, although the overall population incidence was only about 2 to 2.5 per million.

The specific processes by which Felbamate may contribute to the development of aplastic anemia are not yet fully understood; however, according to existing research, it has been found that a considerable proportion of patients who developed aplastic anemia while being treated with felbamate had certain characteristics. Specifically, 42% of these patients had a prior history of cytopenia, 52% had a documented allergy or noteworthy toxicity to another

antiepileptic medicine, and 33% displayed indications of an underlying autoimmune condition (Pellock et al. 2006). Therefore, it is crucial to perform pre-screening for these disorders before to commencing felbamate medication. Therefore, it is crucial to recognize and consider this potential risk. It is imperative to maintain vigilant surveillance of patients receiving felbamate treatment, particularly in the early phases. Frequent evaluations of hematological parameters and prompt intervention in instances of suspected hematological irregularities are imperative in mitigating the risk of potentially fatal aplastic anemia. Healthcare professionals must thoroughly evaluate the therapeutic benefits of Felbamate, specifically in instances of epilepsy that do not respond to therapy, in light of the infrequent but serious possibility of aplastic anemia. The process of making decisions in this context should be informed by a comprehensive assessment of risk factors that are specific to the patient, allowing for a personalized and knowledgeable approach to therapy.

8.1.2 Hepatic Dysfunction

The use of felbamate has been associated with hepatic dysfunction, which is defined by increased levels of liver enzymes and, in certain instances, the development of acute hepatic failure (Wallace, 1996). Globally, a total of 18 instances of hepatic failure have been documented in persons who were administered felbamate. The data was evaluated by a group of hepatologists who concluded that seven of the cases showed a likely connection with felbamate. Based on an estimated worldwide population exposed to felbamate ranging from 130,000 to 170,000 individuals, the incidence rate of hepatic failure is roughly 1 in 7,200 to 9,500 when considering all 18 reported cases. Nevertheless, when considering the seven probable instances, the estimated likelihood of hepatic failure is approximately 1 in 18,500 to 25,000 exposures (Schmidt & Bourgeois, 2000). This level of risk is similar to that observed in cases of hepatic mortality induced by valproate. The occurrence of hepatic failure linked with felbamate commonly manifested approximately 217 days after the commencement of treatment, with a variation spanning from 25 to 939 days. It is worth noting that a significant majority of cases (78%) were seen to involve female patients.

The aforementioned data emphasize the significance of diligent liver monitoring in the administration of Felbamate. Before commencing Felbamate treatment, it is imperative to evaluate pre-existing liver problems as well as the potential influence of other medications on hepatic function. It is imperative to conduct regular monitoring of liver function throughout the duration of treatment in order to promptly identify and address any hepatic complications. Although the precise processes underlying the hepatotoxicity of Felbamate remain incompletely elucidated, it is advisable for doctors to show prudence when administering this medication to patients with pre-existing liver conditions. Furthermore, it is recommended to conduct regular monitoring of hepatic function during the course of treatment.

8.1.3 Hematological Effects

Felbamate has been linked to several hematological side effects, such as leukopenia, neutropenia, and thrombocytopenia. These effects are characterized by a decrease in white blood cell count, neutrophil count, and platelet count, respectively. The hematological abnormalities discussed, although not as severe as aplastic anemia, necessitate careful observation in order to manage potential consequences, such as heightened vulnerability to infections or a propensity for bleeding (Wallace, 1996).

8.1.4 Gastrointestinal Disturbances

The administration of Felbamate has been associated with various gastrointestinal adverse effects, such as nausea, vomiting, abdominal discomfort and diarrhoea (Wallace, 1996). These manifestations can be distressing for individuals receiving this medication, perhaps requiring

modifications in dosage or the implementation of supportive interventions to effectively address gastrointestinal discomfort.

8.1.5 Neurological Effects

Felbamate has been associated with potential deleterious neurological consequences, including Headache (Wallace, 1996), dizziness, ataxia, and somnolence, sleepiness (Wallace, 1996). The aforementioned consequences have the potential to hinder a patient's capacity to engage in routine tasks and necessitate cautious evaluation while administering Felbamate, especially in those with prior neurological disorders.

8.1.6 Psychiatric Manifestations

Certain individuals may exhibit psychiatric symptoms such as changes in mood, irritability, agitation, or nervousness when undergoing treatment with Felbamate (Wallace, 1996). It is imperative to engage in vigilant monitoring of these changes, and healthcare personnel must be adequately equipped to effectively manage any new psychiatric issues that may arise throughout the course of treatment.

8.1.7 Rash and Hypersensitivity Reactions

Skin rashes and hypersensitivity responses have been infrequently observed in association with the usage of Felbamate. The spectrum of reactions can vary, encompassing minor rashes as well as more severe manifestations such as Stevens-Johnson syndrome or toxic epidermal necrolysis, all of which represent critical dermatological crises with potentially fatal outcomes. It is crucial to engage in diligent surveillance for alterations in the skin and promptly cease the administration of Felbamate upon the manifestation of skin reactions in order to prevent the occurrence of serious consequences (Wallace, 1996).

8.1.8 Body weight loss

A reduction in body weight has been observed in 4% of individuals who have been administered felbamate (Wallace, 1996).

8.2 CAUSES OF FELBAMATE TOXICITY

Atropaldehyde, a reactive aldehyde, has been discovered as an intermediary in the metabolism of felbamate in recent investigations. It is conceivable that atropaldehyde's presence may be the cause of felbamate's toxicity. Atropaldehyde might form conjugates with tissue proteins in situations where the system for scavenging free radicals is insufficient, which might be harmful. Notably, erythrocyte glutathione peroxidase activity is reduced in people with felbamate-related aplastic anemia histories. The current study focuses on this hypothesized association. It is recommended to stop taking the medication if significant quantities of the metabolite atropaldehyde are found in the urine.

Dieckhaus et al. (2002) investigated the proposed reactive metabolite of Felbamate, a drug associated with toxicity. Four identified Felbamate metabolites and the suggestion of an intermediate aldehyde, 3-carbamoyl-2-phenylpropionaldehyde (aldehyde carbamate), are discussed. This aldehyde could potentially lead to the formation of a highly reactive aldehyde, 2-phenylpropenal. Interestingly, it is identified as a natural compound known as atropaldehyde. Experimental studies supported atropaldehyde as the reactive metabolite causing Felbamate toxicity. Additionally, research focused on the formation rate of atropaldehyde from aldehyde carbamate, highlighting its pH-dependence. The oxazolidine, related to atropaldehyde, was proposed as a latent form potentially explaining observed blood toxicities. Various experiments supported this hypothesis. In urine samples of patients undergoing Felbamate therapy, evidence for the in vivo formation of the oxazolidine was found. This compound could potentially

oxidize to form the corresponding oxazine-dione, emphasizing its role in Felbamate-associated toxicities.

The dramatically increased prevalence of the human leukocyte (HLA) subtype CW 0703 in a small subset of individuals who had unusual reactions to felbamate is an intriguing discovery. Due to the extreme rarity of this particular HLA subtype in the general population, it may have significance as a marker for identifying people who are more at risk. It is interesting that providing a blood sample to the manufacturer will result in free HLA typing.

8.3 RISK-BENEFIT ASSESSMENT

The Felbamate safety profile emphasizes the importance of risk-benefit appraisal for healthcare providers and patients. Deciding to administer Felbamate requires considering the potential therapeutic benefits and associated risks.

Clinicians must know the patient's medical history, including preexisting conditions, medicines, and contraindications, to assess them. Clinicians have to evaluate the benefits of Felbamate, such as controlling refractory epilepsy, against its risks, including the previously mentioned negative effects. The therapeutic management of felbamate therapy requires personalized treatment programs, careful monitoring, and ongoing review.

Patients also are crucial for risk-benefit assessment. The concepts of informed consent and collaborative decision-making empower patients, allowing them to actively participate in the process of determining their healthcare options. Patients must be advised of the risks of felbamate. Patients can make informed decisions with their doctors with clear and complete information.

For individuals initiating felbamate treatment, it is recommended to conduct a thorough evaluation including a complete blood count and liver function tests prior to commencing therapy. Subsequently, these assessments should be performed bi-weekly during the initial months, followed by monthly checks throughout the first year. As therapy extends beyond a year, the risk tends to decrease, allowing for testing intervals to be extended to every 3 to 4 months. This approach allows for the safe and effective use of Felbamate in clinical practice, maximizing its therapeutic benefits while minimizing its risks.

The Quality Standards Subcommittee of the American Academy of Neurology (AAN) and the American Epilepsy Society published a Practice Advisory in 1999 that describes felbamate-responsive patients. These populations include (1) Lennox-Gastaut syndrome patients over 4 years old who have not responded to initial AED treatment; (2) individuals over 18 years old with refractory partial seizures and unresponsive AED therapy; and (3) felbamate users over 18 months. The Advisory also outlines the group for whom felbamate's risk-to-benefit ratio is uncertain but may be appropriate depending on epileptic disease severity. Children with refractory partial epilepsy who are unable to undergo surgery are included. Patients with generalized epilepsies who do not respond to initial AED treatment are also included. It also includes patients with intolerable sedative or cognitive effects from standard antiepileptics. Lennox-Gastaut syndrome patients under the age of 4 who have not responded to first-line treatment are included. A 3–6-month felbamate trial should be offered to eligible patients. If an adequate dosage does not improve clinical outcomes, felbamate should be discontinued.

Felbamate is not suitable for adults or children with recent epilepsy, those who cannot comply with monitoring and follow-up procedures, those with a history of hematologic adverse events, those with impaired liver function, and those with autoimmune disease or a significant familial predisposition to autoimmune disorders. Patients who cannot comprehend the risk-to-benefit ratio of felbamate medication or lack parental consent are also unsuitable (Pellock et al., 2006).

9. FDA APPROVED LABELLING

Felbamate is available in pharmacies in the form of tablets with strengths of 400 mg and 600 mg, as well as a suspension with a concentration of 600 mg per 5 ml. These formulations are intended for oral use. The recommended dosage is as follows:

Adults: Start with 1200 mg/day divided every 6 to 8 hours, then increase by 600 mg every two weeks, up to a maximum of 3600 mg/day.

Pediatric:

Adjunctive therapy for Lennox-Gastaut: For children between the ages of 2 and 14 years, the recommended first dosage is 15 mg per kg of body weight per day, administered orally and divided into multiple doses every 6 to 8 hours. The dosage may be incrementally raised by 15 mg/kg/day weekly, up to a maximum of 45 mg/kg/day.

For Seizure: Due to a lack of supporting data, it is not approved for use in children under the age of 14 in the treatment of seizures. For those aged 14 years and older, the recommended dosage is equivalent to that of adults.

10. FUTURE DIRECTIONS

Repurposing drugs with unique pharmacological features to develop new neurodegenerative disease treatments is becoming more popular. Felbamate, a substance known for its antiepileptic characteristics, is gaining attention as a promising contender in the field of neuroprotection and neuroinflammation for neurodegenerative disorders. The current study aims to understand its mechanisms and prove its clinical usefulness. Since neurodegenerative illnesses are complex, Felbamate's flexibility and multifaceted pharmacological profile offer potential opportunities for novel therapeutic approaches. The ultimate goal is to reduce these difficult circumstances' impact on individuals and healthcare systems.

10.1 NEUROPROTECTION

Neuroprotection depends on Felbamate's ability to modulate synaptic plasticity and balance excitatory and inhibitory neurotransmission. This oversight may protect against neurodegenerative diseases like Alzheimer's and Parkinson's, which cause neuronal degeneration and synaptic loss. Research is focusing on the molecular processes through which Felbamate enhances neuronal resilience to develop personalized neuroprotection methods.

10.2 NEUROINFLAMMATION

Felbamate's immunomodulatory effects have been studied due to its intricate connection with neurodegenerative pathways. Recent research suggests that Felbamate may reduce neuroinflammation by regulating microglial activation and cytokine production. Anti-inflammatory properties may reduce the neuroinflammatory cascade that causes neuronal damage in illnesses like multiple sclerosis and amyotrophic lateral sclerosis.

10.3 TRANSLATIONAL PROSPECTS

As preclinical investigations show Felbamate's potential in neurodegenerative diseases, clinical translation is necessary. To prove Felbamate's neuroprotective and anti-inflammatory capabilities in humans, clinical trials must prove its safety and efficacy in treating targeted neurodegenerative illnesses.

Felbamate's mechanisms of action in neurodegenerative illnesses must be studied. Understanding how Felbamate interacts with neuroprotection and neuroinflammation molecules might help design targeted therapy and identify patient subgroups that may benefit most from Felbamate-based interventions.

In summary, the transformation of Felbamate from an antiepileptic drug to a neuroprotective and anti-inflammatory treatment for neurodegenerative illnesses seems promising for future research.

11. THERAPEUTIC OPPORTUNITIES FOR FELBAMATE IN THE FIELD OF NEUROLOGY

The field of neurology is currently experiencing a dynamic transformation, characterized by the strategic repurposing of established pharmaceuticals. This strategic repurposing is informed by an improved understanding of the complex pharmacological properties of these medications. Felbamate, a compound that has long been acknowledged for its efficacy in the treatment of epilepsy, is currently attracting growing interest due to its potential therapeutic use in many neurological disorders. We are exploring diverse possibilities of Felbamate in the field of neurology and the promising therapeutic opportunities it presents.

11.1 MANAGEMENT OF EPILEPSY AND BEYOND

The development of Felbamate as an antiepileptic medication has extended beyond its original purpose of treating epilepsy, encompassing a broader range of applications. Despite its continued importance in the treatment of refractory epilepsies, more research needs to be done to determine whether or if it is also beneficial in the management of epilepsy in the presence of other illnesses, such as mood and neurodevelopmental problems. For this reason, it is crucial to evaluate its usefulness in these settings through clinical trials (Zarate et al., 2006).

11.2 MOOD AND ANXIETY DISORDERS

The manipulation of neurotransmitter systems by Felbamate, with a specific focus on its augmentation of GABAergic neurotransmission, offers a potentially fruitful approach for addressing mood and anxiety disorders. Further research is necessary to explore the possibilities of utilizing it as a supplementary treatment for illnesses such as bipolar disorder and generalized anxiety disorder. This has the potential to significantly alter the current therapeutic approaches (Li et al., 2019; Sharma et al., 2008).

11.3 NEURODEVELOPMENTAL DISORDERS

A wide variety of illnesses that affect the development and function of the nervous system are categorized as neurodevelopmental disorders. Felbamate's capacity to balance both excitatory and inhibitory neurotransmission makes it an appealing prospect. This component shows promise, especially when it comes to neurodevelopmental disorders like attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Investigating how this equilibrium affects the basic symptoms and cognitive aspects of these illnesses may open the door to the development of novel therapy strategies.

11.4 PAIN MANAGEMENT

The modulation of NMDA receptors by Felbamate presents new possibilities for the treatment of neuropathic pain. Preliminary studies indicated that it may have potential as an adjuvant therapy for chronic pain conditions that are not effectively managed by conventional treatments. Additional research is required to elucidate the specific analgesic mechanisms and therapeutic efficacy of this phenomenon.

11.5 NEURODEGENERATIVE DISEASES

The neuroprotective and anti-inflammatory characteristics of Felbamate exhibit potential in the treatment of neurodegenerative disorders. Current studies are being conducted to investigate the involvement of this substance in Alzheimer's, Parkinson's, and other medical problems. The

objective is to utilize its potential to reduce the death of neurons and slow down the advancement of these diseases (Mishal et al., 2015).

11.6 COMBINATION THERAPIES

When taken cautiously, felbamate has a favorable safety profile that makes it a promising option for use in combination therapy. Investigating the potential synergistic effects of combining it with established antiepileptic medicines and neuroprotective medications presents a promising avenue for enhancing treatment outcomes in diverse neurological disorders (Wallis & Panizzon, 1995).

11.7 TAILORED APPROACHES

Tailor-made therapy regimens with Felbamate may be possible if patient profiles and biomarkers can be properly analyzed. By using genetic, neuroimaging, and clinical data as guides, personalized therapy might improve outcomes while reducing unwanted side effects.

2. Conclusion

This comprehensive review aims to examine the various therapeutic applications of Felbamate in the field of neurology, going beyond its initial use as an antiepileptic medication. The distinctive pharmacological characteristics of felbamate, such as its effects on synaptic plasticity, GABAergic neurotransmission, and NMDA receptors, highlight its versatility in many neurological scenarios. Significantly, Felbamate exhibits clinical effectiveness not alone in the management of epilepsy, particularly in instances that are resistant to therapy, but also in mood disorders, neurodevelopmental illnesses, pain management, and neurodegenerative diseases. This indicates its increasing significance within the field of neurology. Although Felbamate shows potential for therapeutic efficacy, its administration necessitates a comprehensive comprehension of potential untoward consequences, such as aplastic anemia and hepatic dysfunction, hence mandating a meticulous evaluation of the balance between risks and benefits. To gain a comprehensive understanding of Felbamate's specific processes and to establish its effectiveness and safety in other neurological domains, it is imperative to do additional studies in the future. By investigating potential synergies with established treatments and implementing personalized medicine strategies, the therapeutic effects of this intervention may be further enhanced. Felbamate exemplifies the repurposing of therapies, presenting an opportunity for clinicians and researchers to explore its diverse potential in tackling the complex issues associated with neurological illnesses. This offers a sense of optimism and motivation for further investigation and use.

3. References

1. Asconapé, J. J. (2002). Some common issues in the use of antiepileptic drugs. *Seminars in Neurology*, *22*(1), 27–39. https://doi.org/10.1055/s-2002-33046
2. Beghi, E. (2004). Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. *The Lancet Neurology*, *3*(10), 618–621. https://doi.org/10.1016/S1474-4422(04)00882-8
3. Benedetti, M. S. (2000). Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. *Fundamental & Clinical Pharmacology*, *14*(4), 301–319. https://doi.org/10.1111/j.1472-8206.2000.tb00411.x
4. Borowicz, K. K., Piskorska, B., Kimber-Trojnar, Z., Małek, R., Sobieszek, G., & Czuczwar, S. J. (2004). Is there any future for felbamate treatment? *Polish Journal of Pharmacology*, *56*(3), 289–294. http://www.ncbi.nlm.nih.gov/pubmed/15215558
5. Brodie, M. J. (2010). Antiepileptic drug therapy the story so far. *Seizure*, *19*(10), 650–655. https://doi.org/10.1016/j.seizure.2010.10.027

6. Brown, W. M., & Aiken, S. P. (1998). Felbamate: Clinical and molecular aspects of a unique antiepileptic drug. *Critical Reviews in Neurobiology*, *12*(3), 205–222.
7. https://doi.org/10.1615/CritRevNeurobiol.v12.i3.30
8. Calabresi, P., Cupini, L. M., Centonze, D., Pisani, F., & Bernardi, G. (2003). Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. *Annals of Neurology*, *53*(6), 693–702. https://doi.org/10.1002/ana.10603
9. Cilio, M. R., Kartashov, A. I., & Vigevano, F. (2001). The long-term use of felbamate in children with severe refractory epilepsy. *Epilepsy Research*, *47*(1–2), 1–7. https://doi.org/10.1016/S0920-1211(01)00290-X
10. Corradetti, R., & Pugliese, A. M. (1998). Electrophysiological effects of felbamate. *Life Sciences*, *63*(13), 1075–1088. https://doi.org/10.1016/S0024-3205(98)00230-6
11. Crawford, P. (2002). Interactions between antiepileptic drugs and hormonal contraception. *CNS Drugs*, *16*(4), 263–272. https://doi.org/10.2165/00023210-200216040-00005
12. Czapinski, P., Blaszczyk, B., & Czuczwar, S. (2005). Mechanisms of Action of Antiepileptic Drugs. *Current Topics in Medicinal Chemistry*, *5*(1), 3–14. https://doi.org/10.2174/1568026053386962
13. Dieckhaus, C. M., Thompson, C. D., Roller, S. G., & Macdonald, T. L. (2002). Mechanisms of idiosyncratic drug reactions: the case of felbamate. *Chemico-Biological Interactions*, *142*(1–2), 99–117. https://doi.org/10.1016/S0009-2797(02)00057-1
14. Dozières-Puyravel, B., Nasser, H., Bellavoine, V., Ilea, A., Delanoe, C., & Auvin, S. (2020). Felbamate for infantile spasms syndrome resistant to first-line treatments. *Developmental Medicine and Child Neurology*, *62*(5), 581–586. https://doi.org/10.1111/dmcn.14427
15. Graves, N. M. (1993). Felbamate. *Annals of Pharmacotherapy*, *27*(9), 1073–1081. https://doi.org/10.1177/106002809302700913
16. Grosso, S., Cordelli, D. M., Coppola, G., Franzoni, E., Verrotti, A., Berardi, R., & Balestri, P. (2008). Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review. *European Journal of Neurology*, *15*(9), 940–946. https://doi.org/10.1111/j.1468-1331.2008.02215.x
17. Hanrahan, B., & Carson, R. P. (2023). Felbamate. In *StatPearls*. Elsevier. https://doi.org/10.1016/B978-008055232-3.61739-8
18. Hussain, S. A., Asilnejad, B., Heesch, J., Navarro, M., Ji, M., Shrey, D. W., Rajaraman, R. R., & Sankar, R. (2020). Felbamate in the treatment of refractory epileptic spasms. *Epilepsy Research*, *161*(January), 106284. https://doi.org/10.1016/j.eplepsyres.2020.106284
19. Johannessen Landmark, C., & Patsalos, P. N. (2010). Drug interactions involving the new second- and third-generation antiepileptic drugs. *Expert Review of Neurotherapeutics*, *10*(1), 119–140. https://doi.org/10.1586/ern.09.136
20. Johannessen, S. I., & Tomson, T. (2006). Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? *Clinical Pharmacokinetics*, *45*(11), 1061–1075.
21. https://doi.org/10.2165/00003088-200645110-00002
22. Kaufman, D. W., Kelly, J. P., Anderson, T., Harmon, D. C., & Shapiro, S. (1997). Evaluation of case reports of aplastic anemia among patients treated with felbamate. *Epilepsia*, *38*(12), 1265–1269. https://doi.org/10.1111/j.1528-1157.1997.tb00062.x
23. Laxer, K. D. (1994). Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin. In *Western Journal of Medicine* (Vol. 161, Issue 3, pp. 309–314).
24. Leppik, I. E., Dreifuss, F. E., Pledger, G. W., Graves, N. M., Santilli, N., Drury, I., Tsay,

J. Y., Jacobs, M. P., Bertram, E., & Cereghino, J. J. (1991). Felbamate for partial seizures: results of a controlled clinical trial. *Neurology*, *41*(11), 1785–1789. https://doi.org/10.1212/wnl.41.11.1785

25. Leppik, Ilo E, & White, J. R. (2015). Felbamate. In *The Treatment of Epilepsy* (pp. 472–478). Wiley. https://doi.org/10.1002/9781118936979.ch35
26. Li, X., Wang, H., Chen, Q., Li, Z., Liu, C., Yin, S., & You, Z. (2019). Felbamate produces antidepressant-like actions in the chronic unpredictable mild stress and chronic social defeat stress models of depression. *Fundamental & Clinical Pharmacology*, *33*(6), 621–633. https://doi.org/10.1111/fcp.12466
27. Loiseau, P. (1996). Tolerability of Newer and Older Anticonvulsants. *CNS Drugs*, *6*(2), 148–166. https://doi.org/10.2165/00023210-199606020-00006
28. Löscher, W., Sills, G. J., & White, H. S. (2021a). The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ? In *Epilepsia* (Vol. 62, Issue 3, pp. 596–614).
29. https://doi.org/10.1111/epi.16832
30. Löscher, W., Sills, G. J., & White, H. S. (2021b). The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ? *Epilepsia*, *62*(3), 596–614. https://doi.org/10.1111/epi.16832
31. Mishal, N. M., Arkilo, D., Tang, J., Crawford, J. R., & Wang, S. G. (2015). A Potential Role for Felbamate in TSC- and NF1-Related Epilepsy: A Case Report and Review of the Literature. *Case Reports in Neurological Medicine*, *2015*, 1–8. https://doi.org/10.1155/2015/960746
32. Palmer, K. J., & McTavish, D. (1993). Felbamate. *Drugs*, *45*(6), 1041–1065.
33. https://doi.org/10.2165/00003495-199345060-00008
34. Patsalos, P. N. (2013). Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. *Clinical Pharmacokinetics*, *52*(11), 927–966. https://doi.org/10.1007/s40262-013-0087-0
35. Pellock, J. M., Faught, E., Leppik, I. E., Shinnar, S., & Zupanc, M. L. (2006). Felbamate: consensus of current clinical experience. *Epilepsy Research*, *71*(2–3), 89–101.
36. https://doi.org/10.1016/j.eplepsyres.2006.06.020
37. Perucca, E. (2000). Is there a role for therapeutic drug monitoring of new anticonvulsants? *Clinical Pharmacokinetics*, *38*(3), 191–204. https://doi.org/10.2165/00003088-200038030-00001
38. PERUCCA, E. (1996). The new generation of antiepileptic drugs: advantages and disadvantages. *Br J Clin Pharmacol*, *42*, 531–543. http://www.tandfonline.com/doi/full/10.1517/14728214.4.1.87
39. Rambeck, B., Specht, U., & Wolf, P. (1996). Pharmacokinetic interactions of the new antiepileptic drugs. *Clinical Pharmacokinetics*, *31*(4), 309–324. https://doi.org/10.2165/00003088-199631040-00006
40. Reddy, D. S. (2010). Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. *Expert Review of Clinical Pharmacology*, *3*(2), 183–192.
41. https://doi.org/10.1586/ecp.10.3
42. Schmidt, D. (1993). Felbamate: successful development of a new compound for the treatment of epilepsy. *Epilepsia*, *34 Suppl 7*(s7), S30-3. https://doi.org/10.1111/j.1528-1157.1993.tb04592.x
43. Schmidt, D., & Bourgeois, B. (2000). A risk-benefit assessment of therapies for Lennox-Gastaut syndrome. *Drug Safety*, *22*(6), 467–477. https://doi.org/10.2165/00002018-200022060-00005
44. Sharma, A., Drake, J., Qasimyar, M., & Tucker, S. (2008). Improvement in Depressive Symptoms With Felbamate. *The Primary Care Companion to The Journal of Clinical*

Psychiatry, *10*(03), 252. https://doi.org/10.4088/PCC.v10n0312d

45. Sills, G. J., & Rogawski, M. A. (2020). Mechanisms of action of currently used antiseizure drugs. *Neuropharmacology*, *168*, 107966. https://doi.org/10.1016/j.neuropharm.2020.107966
46. Thakkar, K., Billa, G., Rane, J., Chudasama, H., Goswami, S., & Shah, R. (2015). The rise and fall of felbamate as a treatment for partial epilepsy--aplastic anemia and hepatic failure to blame? *Expert Review of Neurotherapeutics*, *15*(12), 1373–1375. https://doi.org/10.1586/14737175.2015.1113874
47. Vidaurre, J., Gedela, S., & Yarosz, S. (2017). Antiepileptic Drugs and Liver Disease. *Pediatric Neurology*, *77*, 23–36. https://doi.org/10.1016/j.pediatrneurol.2017.09.013
48. Wagner, M. L. (1994). Felbamate: A new antiepileptic drug. In *American Journal of Hospital Pharmacy* (Vol. 51, Issue 13, pp. 1657–1666). https://doi.org/10.1093/ajhp/51.13.1657
49. Wallace, S. J. (1996). A comparative review of the adverse effects of anticonvulsants in children with epilepsy. *Drug Safety*, *15*(6), 378–393. https://doi.org/10.2165/00002018-199615060-00003
50. Wallis, R. A., & Panizzon, K. L. (1995). Felbamate neuroprotection against CA1 traumatic neuronal injury. *European Journal of Pharmacology*, *294*(2–3), 475–482. https://doi.org/10.1016/0014-2999(95)00568-4
51. WHO. (2023). *Epilepsy*. WHo. https://www.who.int/health-topics/epilepsy#tab=tab_1
52. Zarate, C. A., Singh, J., & Manji, H. K. (2006). Cellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder. *Biological Psychiatry*, *59*(11), 1006–1020. https://doi.org/10.1016/j.biopsych.2005.10.021